A systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer’s disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F19%3A43919679" target="_blank" >RIV/00023752:_____/19:43919679 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.eurekaselect.com/162233/article" target="_blank" >http://www.eurekaselect.com/162233/article</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/0929867325666180517094023" target="_blank" >10.2174/0929867325666180517094023</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer’s disease

Popis výsledku v původním jazyce

Alzheimer’s disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity. Its etiology has not been elucidated yet. To date, only one therapeutic approach has been approved for the treatment of AD. The pharmacotherapy of AD has relied on noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, and acetylcholinesterase (AChE) inhibitors (AChEIs) - tacrine, donepezil, rivastigmine and galantamine. Donepezil was able to ameliorate the symptoms related to AD mainly via AChE, but also through reduction of β-amyloid burden. This review presents the overview of donepezilrelated compounds as potential anti-AD drugs developed on the basis of cholinergic hypothesis to act as solely AChE and butyrylcholinesterase (BChE) inhibitors.

Název v anglickém jazyce

A systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer’s disease

Popis výsledku anglicky

Alzheimer’s disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity. Its etiology has not been elucidated yet. To date, only one therapeutic approach has been approved for the treatment of AD. The pharmacotherapy of AD has relied on noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, and acetylcholinesterase (AChE) inhibitors (AChEIs) - tacrine, donepezil, rivastigmine and galantamine. Donepezil was able to ameliorate the symptoms related to AD mainly via AChE, but also through reduction of β-amyloid burden. This review presents the overview of donepezilrelated compounds as potential anti-AD drugs developed on the basis of cholinergic hypothesis to act as solely AChE and butyrylcholinesterase (BChE) inhibitors.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

<a href="/cs/project/LO1611" target="_blank" >LO1611: Udržitelnost pro Národní ústav duševního zdraví</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Medicinal Chemistry

ISSN

0929-8673

e-ISSN

—

Svazek periodika

26

Číslo periodika v rámci svazku

30

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

23

Strana od-do

5625-5648

Kód UT WoS článku

000493956000003

EID výsledku v databázi Scopus

2-s2.0-85075054706